General Information of Drug (ID: DMYIPLH)

Drug Name
AMG-548 Drug Info
Synonyms P38 MAP kinase inhibitor, Amgen
Indication
Disease Entry ICD 11 Status REF
Inflammation 1A00-CA43.1 Terminated [1]
Cross-matching ID
PubChem CID
11167112
CAS Number
CAS 864249-60-5
TTD Drug ID
DMYIPLH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-07265803 DM3E6Q4 Dilated cardiomyopathy BC43.0 Phase 3 [3]
ARRY-797 DMJ48AB Dilated cardiomyopathy BC43.0 Phase 2 [4]
BMS-582949 DMGYXFP Atherosclerosis BD40 Phase 2 [5]
AZD7624 DMEW3K9 Chronic obstructive pulmonary disease CA22 Phase 2 [6]
GSK2269557 DMIN0SV Asthma CA23 Phase 2 [7]
TAK-715 DMZKPI8 Rheumatoid arthritis FA20 Phase 2 [8]
MW150 DMBRVXB Alzheimer disease 8A20 Phase 2 [9]
LY-2228820 DMHXTNW Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
PUR1800 DM6H10N Chronic obstructive pulmonary disease CA22 Phase 1 [11]
ARRY-614 DMXD93K Arthritis FA20 Discontinued in Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Stress-activated protein kinase (p38) TTWELHI NOUNIPROTAC Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019881)
2 p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel. 2005 Jul;8(4):421-30.
3 Clinical pipeline report, company report or official report of Pfizer
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33.
6 Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
7 Evaluation of WO2012032067 and WO2012055846: two selective PI3Kdelta inhibitors, which is GSK-2269557. Expert Opin Ther Pat. 2012 Aug;22(8):965-70.
8 Inhibition of Wnt/beta-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Idelta/ . Chem Biol. 2011 Apr 22;18(4):485-94.
9 p38alpha MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10245-E10254.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959).
11 Clinical pipeline report, company report or official report of Pulmatrix Lexington, MA
12 Cmpany report (Arraybiopharma)